Financial Sense Advisors Inc. Purchases New Holdings in Edwards Lifesciences Co. (NYSE:EW)

Financial Sense Advisors Inc. acquired a new position in Edwards Lifesciences Co. (NYSE:EW) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 10,200 shares of the medical research company’s stock, valued at approximately $975,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. DSM Capital Partners LLC purchased a new position in Edwards Lifesciences during the fourth quarter valued at $28,000. Turtle Creek Wealth Advisors LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth about $34,000. Riverview Trust Co bought a new position in Edwards Lifesciences in the 1st quarter worth about $34,000. Pingora Partners LLC purchased a new stake in Edwards Lifesciences during the 4th quarter valued at about $38,000. Finally, SRS Capital Advisors Inc. increased its stake in Edwards Lifesciences by 292.6% during the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after purchasing an additional 474 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $91.09 on Thursday. The stock has a market cap of $54.89 billion, a P/E ratio of 39.26, a P/E/G ratio of 3.34 and a beta of 1.11. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The stock’s fifty day moving average is $87.99 and its 200 day moving average is $85.56. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. The Goldman Sachs Group started coverage on shares of Edwards Lifesciences in a report on Thursday, May 30th. They set a “buy” rating and a $107.00 price target on the stock. Deutsche Bank Aktiengesellschaft raised Edwards Lifesciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $86.00 to $103.00 in a report on Tuesday, May 14th. Wells Fargo & Company upped their price target on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a report on Friday, April 26th. Citigroup upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $98.00 to $105.00 in a report on Wednesday, May 22nd. Finally, Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $95.18.

Insider Buying and Selling at Edwards Lifesciences

In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $92.32, for a total value of $1,329,408.00. Following the completion of the transaction, the vice president now owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $92.32, for a total value of $1,329,408.00. Following the transaction, the vice president now directly owns 173,849 shares of the company’s stock, valued at approximately $16,049,739.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Bernard J. Zovighian purchased 580 shares of the company’s stock in a transaction on Monday, May 6th. The stock was acquired at an average price of $85.74 per share, with a total value of $49,729.20. Following the completion of the purchase, the chief executive officer now directly owns 3,268 shares in the company, valued at $280,198.32. The disclosure for this purchase can be found here. Insiders have sold 90,499 shares of company stock valued at $7,866,511 over the last 90 days. 1.27% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.